Giuseppe Novelli Selected Research

Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)

8/2021	Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer.
1/2016	The human rs1050286 polymorphism alters LOX-1 expression through modifying miR-24 binding.
3/2008	The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization.
6/2007	Genotyping OLR1 gene: a genomic biomarker for cardiovascular diseases.
1/2006	Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders.
7/2005	In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giuseppe Novelli Research Topics

Disease

25	COVID-19 01/2023 - 01/2020
17	Neoplasms (Cancer) 02/2023 - 04/2004
12	Atherosclerosis 08/2021 - 07/2005
9	Laminopathies 10/2021 - 06/2005
9	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2020 - 03/2002
9	Myotonic Dystrophy (Dystrophia Myotonica) 02/2017 - 06/2005
8	Inflammation (Inflammations) 01/2023 - 01/2012
8	Infections 01/2023 - 01/2010
6	Psoriatic Arthritis 05/2024 - 11/2010
6	Lipodystrophy 01/2023 - 06/2005
6	Deafness (Deaf Mutism) 01/2023 - 02/2009
6	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 02/2006
6	Prostatic Neoplasms (Prostate Cancer) 10/2007 - 09/2002
5	Cardiomyopathies (Cardiomyopathy) 01/2023 - 06/2012
5	Familial Partial Lipodystrophy (Dunnigan Syndrome) 01/2021 - 08/2002
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 12/2005
5	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 07/2016 - 07/2005
5	Cystic Fibrosis (Mucoviscidosis) 08/2015 - 09/2002
4	Diabetic Neuropathies (Diabetic Neuropathy) 01/2024 - 08/2014
4	Atrophy 10/2022 - 01/2005
4	Pneumonia (Pneumonitis) 06/2022 - 03/2004
4	Carcinogenesis 08/2021 - 01/2011
4	Type 2 Diabetes Mellitus (MODY) 08/2020 - 12/2013
4	Macular Degeneration (Age-Related Maculopathy) 03/2019 - 01/2013
4	Hypersensitivity (Allergy) 01/2017 - 03/2004
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 02/2024 - 01/2021
3	Obesity 01/2024 - 01/2011
3	Premature Aging 01/2022 - 04/2007
3	Breast Neoplasms (Breast Cancer) 01/2021 - 04/2016
3	Osteoporosis 11/2020 - 01/2005
3	HIV Infections (HIV Infection) 01/2018 - 03/2014
3	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2018 - 03/2014
3	Progeria (Hutchinson Gilford Syndrome) 06/2012 - 12/2009
3	Myocardial Infarction 03/2008 - 07/2005
2	Rheumatoid Arthritis 02/2024 - 01/2017
2	Myocarditis (Carditis) 01/2023 - 10/2022
2	Disease Progression 01/2023 - 10/2022
2	Microcephaly 10/2022 - 02/2009
2	Friedreich Ataxia (Friedreich's Ataxia) 01/2022 - 01/2020
2	Drug-Related Side Effects and Adverse Reactions 01/2021 - 01/2010
2	Thrombosis (Thrombus) 01/2021 - 07/2013
2	Disease Susceptibility (Diathesis) 01/2019 - 07/2008
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 03/2016
2	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 03/2016
2	Muscular Atrophy (Muscle Atrophy) 12/2018 - 09/2012
2	Parkinson Disease (Parkinson's Disease) 01/2018 - 01/2015
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2018 - 10/2016
2	Neuromuscular Diseases (Neuromuscular Disease) 07/2016 - 05/2010

Drug/Important Bio-Agent (IBA)

26	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2002
21	Biomarkers (Surrogate Marker)IBA 05/2024 - 06/2007
15	MicroRNAs (MicroRNA)IBA 01/2024 - 05/2010
10	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 09/2002
10	Lamin Type A (Lamin A)IBA 10/2021 - 08/2002
7	Nevirapine (Viramune)FDA Link 01/2018 - 01/2010
6	Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA 08/2021 - 07/2005
5	AutoantibodiesIBA 01/2023 - 01/2019
5	AntibodiesIBA 10/2022 - 01/2014
5	VaccinesIBA 06/2022 - 07/2008
5	Protein Isoforms (Isoforms)IBA 06/2017 - 07/2005
5	oxidized low density lipoproteinIBA 03/2016 - 01/2006
5	prelamin AIBA 09/2014 - 06/2005
5	AndrogensIBA 10/2007 - 04/2004
4	Messenger RNA (mRNA)IBA 12/2023 - 10/2020
4	Antiviral Agents (Antivirals)IBA 02/2023 - 12/2020
4	Interferon Type IIBA 01/2023 - 10/2020
4	Neutralizing AntibodiesIBA 01/2022 - 12/2020
4	NAD (NADH)IBA 08/2020 - 08/2014
4	LaminsIBA 04/2018 - 08/2002
4	HLA-C Antigens (HLA-C)IBA 01/2018 - 03/2002
4	Scavenger Receptors (Scavenger Receptor)IBA 01/2012 - 07/2005
3	Peptides (Polypeptides)IBA 01/2023 - 01/2021
3	CytokinesIBA 01/2023 - 01/2006
3	ChromatinIBA 12/2020 - 10/2005
3	Oxidized LDL ReceptorsIBA 01/2019 - 01/2011
3	azelastine (Optivar)FDA LinkGeneric 06/2017 - 06/2007
3	3' Untranslated Regions (3' UTR)IBA 01/2017 - 02/2006
3	LectinsIBA 03/2016 - 01/2011
3	HLA-C*06 antigenIBA 05/2011 - 03/2002
2	Calcitriol Receptors (Calcitriol Receptor)IBA 02/2024 - 12/2018
2	Tumor Necrosis Factor InhibitorsIBA 02/2024 - 01/2017
2	EnzymesIBA 01/2023 - 09/2012
2	GadoliniumIBA 01/2023 - 06/2015
2	Exonucleases (3' 5' Exonuclease)IBA 01/2023 - 08/2013
2	Interleukin-6 (Interleukin 6)IBA 01/2023 - 05/2020
2	Interleukin-10 (Interleukin 10)IBA 01/2023 - 01/2019
2	mRNA VaccinesIBA 10/2022 - 06/2022
2	Angiotensin-Converting Enzyme 2IBA 10/2022 - 01/2021
2	Retinaldehyde (Retinal)IBA 10/2022 - 02/2009
2	COVID-19 VaccinesIBA 06/2022 - 01/2021
2	FrataxinIBA 01/2022 - 01/2020
2	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2022 - 01/2021
2	Mitochondrial DNA (mtDNA)IBA 08/2020 - 01/2016
2	Histones (Histone)IBA 01/2019 - 06/2008
2	Small Interfering RNA (siRNA)IBA 01/2019 - 03/2016
2	ElementsIBA 12/2018 - 05/2010
2	AntigensIBA 01/2018 - 09/2015
2	Levodopa (L Dopa)FDA LinkGeneric 01/2018 - 06/2007
2	Histone Deacetylase InhibitorsIBA 04/2016 - 06/2007

Therapy/Procedure

17	Therapeutics 05/2024 - 06/2007
3	Precision Medicine 02/2020 - 01/2015